174 related articles for article (PubMed ID: 15536684)
1. New type of effective antifungal treatment identified.
Bosch X
Lancet Oncol; 2004 Nov; 5(11):645. PubMed ID: 15536684
[No Abstract] [Full Text] [Related]
2. Caspofungin versus liposomal amphotericin B for empirical therapy.
Schneemann M; Imhof A
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675094
[No Abstract] [Full Text] [Related]
3. Caspofungin versus liposomal amphotericin B for empirical therapy.
Danaher PJ
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675092
[No Abstract] [Full Text] [Related]
4. Caspofungin versus liposomal amphotericin B for empirical therapy.
Tattevin P; Bareau B; Camus C
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675091
[No Abstract] [Full Text] [Related]
5. An open study of the comparative efficacy and safety of caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with haematological malignancy.
Ellis M; Frampton C; Joseph J; Alizadeh H; Kristensen J; Hauggaard A; Shammas F
J Med Microbiol; 2006 Oct; 55(Pt 10):1357-1365. PubMed ID: 17005784
[TBL] [Abstract][Full Text] [Related]
6. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
[TBL] [Abstract][Full Text] [Related]
7. Caspofungin versus liposomal amphotericin B for empirical therapy.
Jones BL; McLintock LA
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675090
[No Abstract] [Full Text] [Related]
8. [Caspofungin in the replacement of amphotericin B in the treatment of fungal diseases].
Yang W; He B
Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(1):53. PubMed ID: 15808079
[No Abstract] [Full Text] [Related]
9. [Systemic antifungals. Pharmacodynamics and pharmacokinetics].
Catalán M; Montejo JC
Rev Iberoam Micol; 2006 Mar; 23(1):39-49. PubMed ID: 16499430
[TBL] [Abstract][Full Text] [Related]
10. Trichosporon asahii infection treated with caspofungin combined with liposomal amphotericin B.
Bassetti M; Bisio F; Di Biagio A; Pierri I; Balocco M; Soro O; Cruciani M; Bassetti D
J Antimicrob Chemother; 2004 Aug; 54(2):575-7. PubMed ID: 15231763
[No Abstract] [Full Text] [Related]
11. Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin.
Maschmeyer G; Glasmacher A
Mycoses; 2005 Jul; 48(4):227-34. PubMed ID: 15982202
[TBL] [Abstract][Full Text] [Related]
12. Caspofungin: a major breakthrough in treatment of systemic fungal infections.
Agarwal MB; Rathi SA; Ratho N; Subramanian R
J Assoc Physicians India; 2006 Dec; 54():943-8. PubMed ID: 17334012
[TBL] [Abstract][Full Text] [Related]
13. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK.
Bruynesteyn K; Gant V; McKenzie C; Pagliuca T; Poynton C; Kumar RN; Jansen JP
Eur J Haematol; 2007 Jun; 78(6):532-9. PubMed ID: 17419744
[TBL] [Abstract][Full Text] [Related]
14. [Successful treatment with caspofungin of an invasive candidosis resistant to liposomal amphotericin B in a neutropenic patient].
Rome A; André N; Michel A; Coze C; Gentet JC; Bernard JL
Arch Pediatr; 2006 Dec; 13(12):1556-7. PubMed ID: 17049216
[No Abstract] [Full Text] [Related]
15. Caspofungin and amphotericin B for disseminated Fusarium verticillioides in leukemia.
Makowsky MJ; Warkentin DI; Savoie ML
Ann Pharmacother; 2005; 39(7-8):1365-6. PubMed ID: 15956243
[No Abstract] [Full Text] [Related]
16. Antifungal therapy in patients with fever and neutropenia--more rational and less empirical?
Klastersky J
N Engl J Med; 2004 Sep; 351(14):1445-7. PubMed ID: 15459307
[No Abstract] [Full Text] [Related]
17. FK 463.
Drugs R D; 1999 Feb; 1(2):172-3. PubMed ID: 10566017
[No Abstract] [Full Text] [Related]
18. Comment: caspofungin acetate for treatment of invasive fungal infections.
Chan J
Ann Pharmacother; 2003 Apr; 37(4):595. PubMed ID: 12659624
[No Abstract] [Full Text] [Related]
19. Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: analysis of results from the Caspofungin Empirical Therapy Study.
de Pauw BE; Sable CA; Walsh TJ; Lupinacci RJ; Bourque MR; Wise BA; Nguyen BY; DiNubile MJ; Teppler H
Transpl Infect Dis; 2006 Mar; 8(1):31-7. PubMed ID: 16623818
[TBL] [Abstract][Full Text] [Related]
20. Caspofungin in the treatment of invasive fungal infections.
Keady S; Thacker M
Intensive Crit Care Nurs; 2006 Feb; 22(1):59-62. PubMed ID: 16006127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]